Related content

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

By Ekman Simon   Fröödin Jan-Erik   Harmenberg Johan   Bergman Antonina   Hedlund ÅÅsa   Dahg Pia   Alvfors Carina   Stååhl Birgitta   Bergströöm Stefan   Bergqvist Michael  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Expression of vascular endothelial growth factorC and vascular endothelial growth factor receptor3 in esophageal squamous cell carcinoma

By                        

Oncology Letters, Vol. 7, Iss. 4, 2014-01 ,pp. : 1027-1032

Spandidos Publications

Access to resources Recommend Favorite

The insulin-like growth factor-1 and expression of its binding protein3 in chronic hepatitis C and hepatocellular carcinoma

By                

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1337-1345

Spandidos Publications

Access to resources Recommend Favorite

Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma

By Rasmuson Torgny   Grankvist Kjell   Jacobsen Jan   Olsson Tommy   Ljungberg Börje  

Acta Oncologica, Vol. 43, Iss. 8, 2004-12 ,pp. : 744-748

Informa Healthcare

Access to resources Recommend Favorite

miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor

By Guo Jinling   Xia Bairong   Meng Fanling   Lou Ge  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1557-1564

Springer Publishing Company

Access to resources Recommend Favorite